FIRST QUARTER 2023
Figures in parentheses refer to the corresponding period last year, unless otherwise specified.
- Net sales amounted to
SEK 365.8 million (283.9), an increase ofSEK 82.0 million , or 29% (excluding foreign exchange effects, 19%). -
Net sales in the Paediatrics segment amounted to
SEK 306.0 million (222.5), an increase of 37% (excluding foreign exchange effects, 27%). -
Net sales in the
Adult Health segment amounted toSEK 56.6 million (60.8), a decrease of 7% (excluding foreign exchange effects a decrease of 14%). -
Operating expenses amounted to
SEK 114.5 million (106.9), an increase ofSEK 7.6 million (7%). Operating expenses, excluding items affecting comparability, increased by 10% toSEK 112.1 million (102.2). -
Operating profit increased by 55% to
SEK 148.0 million (95.3), which corresponds to an operating margin of 40% (34%). Adjusted operating profit increased by 50% toSEK 150.4 million (100.0), which corresponds to an adjusted operating margin of 41% (35%). -
Profit after tax amounted to
SEK 115.9 million (76.3), an increase of 52%. -
Earnings per share amounted to
SEK 1.15 (0.76) before and after dilution[1]. -
Cash flow amounted to
SEK 93.7 million (85.8). -
Cash and cash equivalents at
31 March 2023 amounted toSEK 1,580.8 million (SEK 1,571.7 million at 31 March 2022).
Key events in the first quarter of 2023
- On 29 March, BioGaia announced that the company's CEO
Isabelle Ducellier intends to leave the company and take up employment with another company.Isabelle Ducellier will remain in her position until30 September 2023 . - On 31 March, BioGaia announced that the company is launching a probiotic skin ointment for infants and children, Aldermis.
Key events after the end of the first quarter
- On 26 April, BioGaia presented the preliminary results for the first quarter of 2023.
-
On 27 April, BioGaia announced that the company is launching the Prenatal Care product for women before and during pregnancy.
[1] In view of the 5:1 share split, which took place in
CEO's comments
Following on from another record year in 2022, when sales passed
In the
With net sales of
After a surge in sales of 52% in EMEA in 2022 due to the recovery from Covid, sales of
Excellent results in
Despite cautious consumer spending during times of high inflation and the concern about the future economic outlook, demand for clinically proven probiotics products remains healthy.
It is also worth noting that BioGaia's financial situation is very robust, and during times such as these with limited access to new capital in the biotech sector, we have no such needs in order to drive our growth, develop new products, finance possible acquisitions, and continue to disburse attractive dividends.
Lastly, as announced on 29 March, I have, with mixed feelings, decided to leave BioGaia and instead join
President and CEO BioGaia
Teleconference: Investors, analysts and the media are invited to take part in a teleconference on the interim management statement to be held today,
Follow us:
Subscribe to BioGaia press releases here
LinkedIn here
Contacts:
Email: ako@biogaia.se
Phone: +46 735 00 11 11
Email: mis@biogaia.se
Phone: +46 730 95 61 50
About BioGaia
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the
This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at
https://news.cision.com/biogaia/r/biogaia-ab--interim-management-statement---january---march-2023,c3764271
https://mb.cision.com/Main/3271/3764271/2035135.pdf
(c) 2023 Cision. All rights reserved., source